Xeloda (zah-LOE-duh, capecitabine), the first ORAL drug for metastatic breast cancer

June 1998

Roche is now marketing Xeloda (zah-LOE-duh, capecitabine),the first ORAL drug for metastatic breast cancer.

It's for patients who can't take, or are resistant to, treatmentwith paclitaxel (Taxol) and anthracyclines (Adriamycin, etc).

Xeloda is a prodrug of 5-FU (5-fluorouracil). It'smetabolized to 5-FU by enzymes in tumor cells.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote